Login to Your Account

No Zoptrex but hope springs Aeterna for FDA-bound AGHD test

By Randy Osborne
Staff Writer

Monday, May 1, 2017

Aeterna Zentaris Inc.’s conference call with investors on the phase III failure of Zoptrex in endometrial cancer ended quickly and the company put off until its first-quarter earnings report next Tuesday details about what the blowup means for the company’s future.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription